Loss of HER2 and decreased T-DM1 efficacy in HER2 positive advanced breast cancer treated with dual HER2 blockade: the SePHER Study

to related objects

Location
Deutsche Nationalbibliothek Frankfurt am Main
ISSN
1756-9966
Extent
Online-Ressource
Language
Englisch
Notes
online resource.

Bibliographic citation
Loss of HER2 and decreased T-DM1 efficacy in HER2 positive advanced breast cancer treated with dual HER2 blockade: the SePHER Study ; volume:39 ; number:1 ; day:10 ; month:12 ; year:2020 ; pages:1-14 ; date:12.2020
Journal of experimental & clinical cancer research ; 39, Heft 1 (10.12.2020), 1-14, 12.2020

Creator
Bon, Giulia
Pizzuti, Laura
Laquintana, Valentina
Loria, Rossella
Porru, Manuela
Marchiò, Caterina
Krasniqi, Eriseld
Barba, Maddalena
Maugeri-Saccà, Marcello
Gamucci, Teresa
Berardi, Rossana
Livi, Lorenzo
Ficorella, Corrado
Natoli, Clara
Cortesi, Enrico
Generali, Daniele
La Verde, Nicla
Cassano, Alessandra
Bria, Emilio
Moscetti, Luca
Michelotti, Andrea
Adamo, Vincenzo
Zamagni, Claudio
Tonini, Giuseppe
Barchiesi, Giacomo
Mazzotta, Marco
Marinelli, Daniele
Tomao, Silverio
Marchetti, Paolo
Valerio, Maria Rosaria
Mirabelli, Rosanna
Russo, Antonio
Fabbri, Maria Agnese
D’Ostilio, Nicola
Veltri, Enzo
Corsi, Domenico
Garrone, Ornella
Paris, Ida
Sarobba, Giuseppina
Giotta, Francesco
Garufi, Carlo
Cazzaniga, Marina
Medico, Pietro Del
Roselli, Mario
Sanguineti, Giuseppe
Sperduti, Isabella
Sapino, Anna
De Maria, Ruggero
Leonetti, Carlo
Di Leo, Angelo
Ciliberto, Gennaro
Falcioni, Rita
Vici, Patrizia
Contributor
SpringerLink (Online service)

DOI
10.1186/s13046-020-01797-3
URN
urn:nbn:de:101:1-2021011720374232765736
Rights
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
Last update
15.08.2025, 7:28 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Show original at data provider

Associated

  • Bon, Giulia
  • Pizzuti, Laura
  • Laquintana, Valentina
  • Loria, Rossella
  • Porru, Manuela
  • Marchiò, Caterina
  • Krasniqi, Eriseld
  • Barba, Maddalena
  • Maugeri-Saccà, Marcello
  • Gamucci, Teresa
  • Berardi, Rossana
  • Livi, Lorenzo
  • Ficorella, Corrado
  • Natoli, Clara
  • Cortesi, Enrico
  • Generali, Daniele
  • La Verde, Nicla
  • Cassano, Alessandra
  • Bria, Emilio
  • Moscetti, Luca
  • Michelotti, Andrea
  • Adamo, Vincenzo
  • Zamagni, Claudio
  • Tonini, Giuseppe
  • Barchiesi, Giacomo
  • Mazzotta, Marco
  • Marinelli, Daniele
  • Tomao, Silverio
  • Marchetti, Paolo
  • Valerio, Maria Rosaria
  • Mirabelli, Rosanna
  • Russo, Antonio
  • Fabbri, Maria Agnese
  • D’Ostilio, Nicola
  • Veltri, Enzo
  • Corsi, Domenico
  • Garrone, Ornella
  • Paris, Ida
  • Sarobba, Giuseppina
  • Giotta, Francesco
  • Garufi, Carlo
  • Cazzaniga, Marina
  • Medico, Pietro Del
  • Roselli, Mario
  • Sanguineti, Giuseppe
  • Sperduti, Isabella
  • Sapino, Anna
  • De Maria, Ruggero
  • Leonetti, Carlo
  • Di Leo, Angelo
  • Ciliberto, Gennaro
  • Falcioni, Rita
  • Vici, Patrizia
  • SpringerLink (Online service)

Other Objects (12)

Tumor-infiltrating lymphocytes in HER2-positive breast cancer treated with neoadjuvant chemotherapy and dual HER2-blockade

Tumor-infiltrating lymphocytes in HER2-positive breast cancer treated with neoadjuvant chemotherapy and dual HER2-blockade

Dual HER2 blockade: preclinical and clinical data

Dual HER2 blockade: preclinical and clinical data

Prognostic impact of HER2 biomarker levels in trastuzumab-treated early HER2-positive breast cancer

Prognostic impact of HER2 biomarker levels in trastuzumab-treated early HER2-positive breast cancer

Comparison of tumors with HER2 overexpression versus HER2 amplification in HER2-positive breast cancer patients

Comparison of tumors with HER2 overexpression versus HER2 amplification in HER2-positive breast cancer patients

HER2 heterogeneity and resistance to anti-HER2 antibody-drug conjugates

HER2 heterogeneity and resistance to anti-HER2 antibody-drug conjugates

Dual targeting non-overlapping epitopes in HER2 domain IV substantially enhanced HER2/HER2 homodimers and HER2/EGFR heterodimers internalization leading to potent antitumor activity in HER2-positive human gastric cancer

Dual targeting non-overlapping epitopes in HER2 domain IV substantially enhanced HER2/HER2 homodimers and HER2/EGFR heterodimers internalization leading to potent antitumor activity in HER2-positive human gastric cancer

HER2 quantitative continuous scoring for accurate patient selection in HER2 negative trastuzumab deruxtecan treated breast cancer

HER2 quantitative continuous scoring for accurate patient selection in HER2 negative trastuzumab deruxtecan treated breast cancer

HER2 amplification by next-generation sequencing to identify HER2-positive invasive breast cancer with negative HER2 immunohistochemistry

HER2 amplification by next-generation sequencing to identify HER2-positive invasive breast cancer with negative HER2 immunohistochemistry

Differential response of HER2-positive breast cancer to anti-HER2 therapy based on HER2 protein expression level

Differential response of HER2-positive breast cancer to anti-HER2 therapy based on HER2 protein expression level

Comprehensive genomic characterization of HER2-low and HER2-0 breast cancer

Comprehensive genomic characterization of HER2-low and HER2-0 breast cancer

Häufigkeit der EGFR- und HER2-Ausprägung sowie HER2-Genamplifikation beim Gallengangskarzinom

Hochschulschrift

Häufigkeit der EGFR- und HER2-Ausprägung sowie HER2-Genamplifikation beim Gallengangskarzinom

Exploratory analysis of serum HER2 extracellular domain for HER2 positive gastric cancer treated with SOX plus trastuzumab

Exploratory analysis of serum HER2 extracellular domain for HER2 positive gastric cancer treated with SOX plus trastuzumab

Related objects